The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.
Patients with benign or malignant hematological diseases such as leukemia, lymphoma, thalassemia, aplastic anemia, etc. diagnosed by NCCN guidelines, and requiring allogeneic hematopoietic stem cell transplantation as determined by the researchers;
Age 3-65 years old;
Weight 10Kg-100Kg;
Eastern Cooperative Oncology Group (ECOG) score ≤3;
patients with nonhematologic diseases who are not eligible for transplantation or who do not wish to receive transplantation;
patients with an expected survival of less than 1 month;
patients with previous autologous or allogeneic hematopoietic stem cell transplantation;
pregnant patients;